Last reviewed · How we verify
Phase III Study of CHOP-14 Plus or Minus Alemtuzumab in Peripheral T-cell Lymphoma of the Elderly (A-CHOP-14)
Peripheral T cell lymphomas comprise 10-15% of all malignant lymphomas. The prognosis is significantly worse than that of aggressive B cell lymphomas. The prospects of elderly patients are especially poor, with an estimated disease free survival of only 25% after three years. Previous phase II trials have demonstrated a significant activity of the monoclonal anti CD52 antibody alemtuzumab in primary and relapsed T cell lymphoma. The investigators thus propose to investigate the value of adjuvant alemtuzumab in combination with dose dense CHOP-14 in patients with previously untreated peripheral T cell lymphoma.
Details
| Lead sponsor | University of Göttingen |
|---|---|
| Phase | Phase 3 |
| Status | UNKNOWN |
| Enrolment | 274 |
| Start date | 2008-02 |
| Completion | 2014-03 |
Conditions
- Peripheral T Cell Lymphoma, Unspecified
- Angioimmunoblastic Lymphadenopathy
- Extranodal NK/T-cell Lymphoma
Interventions
- alemtuzumab
- chemotherapy
Primary outcomes
- Event free survival — 3 years
Countries
Germany